Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

MOTIV BTK Randomized Controlled Trial

NCT: NCT05406622 · ACTIVE_NOT_RECRUITING

NCT IDNCT05406622
StatusACTIVE_NOT_RECRUITING
Start Date2022-06-10
Completion2030-03-31
SponsorREVA Medical, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

Pre-market clinical evaluation of the MOTIV Sirolimus-Eluting Bioresorbable Scaffold for the planned treatment of infrapopliteal lesions.

Frequently Asked Questions

What is MOTIV BTK Randomized Controlled Trial?

MOTIV BTK Randomized Controlled Trial is a clinical trial registered under NCT05406622. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05406622?

The current status of NCT05406622 (MOTIV BTK Randomized Controlled Trial) is: ACTIVE_NOT_RECRUITING.

When did MOTIV BTK Randomized Controlled Trial start?

MOTIV BTK Randomized Controlled Trial started on 2022-06-10.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑